Expert Interviews

Dr. Patel and Dr. Yu review the rationale for targeting HER3 as a novel approach to address acquired resistance in EGFR-mutant NSCLC.

The panelists summarize their approaches to choosing frontline treatment for advanced clear cell RCC, balancing long-term and short-term efficacy data on IO-IO versus IO-TKI regimens based on recent study results.

Elizabeth Plimack, MD, reviews a network meta-analysis comparing progression free survival and overall survival outcomes for lenvatinib plus pembrolizumab versus other first line regimens for metastatic clear cell renal cell carcinoma across multiple trials.

Experts present findings on blinatumomab consolidation therapy from the Phase 3 ECOG-ACRIN E1910 trial in adult patients with newly diagnosed B-lineage acute lymphoblastic leukemia who achieved measurable residual disease-negative remission.

Experts provide the first report of results from the Phase 3 PhALLCON trial comparing initial therapy with ponatinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Prophylactic cranial irradiation may not be worthwhile for treating patients with extensive-stage small cell lung cancer based on conflicting data, according to Gregory Peter Kalemkerian, MD.

FDA-approved immunotherapy options such as atezolizumab and durvalumab have produced substantial benefits in certain groups of patients with extensive-stage small cell lung cancer, says Gregory Peter Kalemkerian, MD.

Carey K. Anders, MD, concludes with a look toward the future of HER2+ breast cancer treatment and provides advice to community oncologists treating patients with breast cancer.

An overview of the design and rationale for the phase 2 BRIDGET study looking at the addition of tucatinib to HER2-directed antibody therapy in breast cancer.

An expert on metastatic breast cancer provides clinical insights gleaned from the HER2CLIMB-02 trial and discusses the design and rationale of the ongoing HER2CLIMB-05 study.

Following SABCS 2023, Carey K. Anders, MD, reviews recent updates from the KATHERINE and APHINITY clinical trials in HER2+ breast cancer.

The panelists conclude their discussion on HER2-positive breast cancer by underscoring the importance of preventive measures for brain metastases, enhanced strategies for managing leptomeningeal disease, and improved approaches to handle treatment-related toxicity.

Heather Moore, CPP, PharmD, shares expert insights on managing T-DXd-related adverse effects, including prophylactic measures for nausea and strategies for monitoring and management of ILD.

Rani Bansal, MD explores recent findings suggesting a risk of radiation necrosis in patients undergoing treatment with ADCs and concurrent radiotherapy for brain metastases and discusses the potential implications for future treatment approaches.

The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.

The expert panel provides a comprehensive overview of the COSMOS-CRC-03 study and touch on the importance of also looking at real-world data.

An overview of prospective trial data surrounding MRD testing in early-stage CRC and the impact of these findings on the overall treatment landscape.

Expert medical oncologists examine remaining unmet needs in managing EGFR-positive lung cancer, including overcoming resistance to initial EGFR-directed therapy. The panel discusses ongoing trials targeting these needs.

Dr. Yu and Dr. Patel provide an overview of current standards and recent advances in the treatment landscape for EGFR-mutated NSCLC, emphasizing the critical role of comprehensive genomic profiling in guiding optimal therapy selection and sequencing.

Dr. Gregory Gan presents Case 4, featuring a 71-year-old diagnosed with Stage IIIA NSCLC experiencing pneumonitis following Chemo-IO treatment, prompting a discussion with expert insight on the monitoring and management of this condition.